Presented by LabRoots
Self-isolation and quarantine measures taken by many nations during the SARS-CoV-2 (COVID-19) pandemic have had a considerable impact on research laboratories, but scientists have adapted quickly and continue to support the many studies on the virus that are underway. These investigations range from research on immunopathology, diagnostics and therapeutics to understanding the biomarkers and epigenetics underlying the susceptibility of different individuals. Academic core facilities such as flow cytometry labs are essential support services that researchers rely on daily for these studies, and they have been working diligently to adjust to the changing times.

We have invited leaders from academic core labs and the life sciences industry who support the discovery and therapeutics efforts against COVID-19. They will discuss the best practices that are being adopted to minimize individual risk while handling COVID-19 infected specimens, emerging research areas and the use of cell sorting in a workflow for therapeutic antibody screening and identification.

Sony Biotechnology is proud to support and work with teams like these across the globe.

Key learning objectives

  • Hear about how research labs are adapting to support COVID-19 research
  • Learn about flow cytometry approaches used for studying COVID-19 immunopathology
  • Get more information on the use of flow cytometry in the discovery of COVID-19 neutralizing antibodies

 

Who should attend

This panel discussion will benefit all researchers and service providers engaged in COVID-19 research, including those exploring different technologies for the development of antiviral antibody therapeutics.

 

Speakers

Photo of Frederic LeducFrederic Leduc
CEO, Immune BioSolutions
Photo of Jeff MilushJeff Milush
Associate Professor, Medicine
University of California, San Francisco
Photo of Jeff MilushPatricia Rogers
Associate Director, Flow Cytometry Facility
Broad Institute of MIT and Harvard